Home
Click to Print  |  Standard View

5 Months To Go: CFC Inhaler Phase-Out Deadline Looms

July 8, 2008

With only five months to go until the phase-out of CFC propellants for albuterol inhalers, the FDA notes that up to 55% of inhaler users have still not transitioned to HFA medications. “As respiratory therapists, it’s time to act and make sure our patients are educated and aware of the changes that will occur,” said Tom Kallstrom, Chief Operating Officer of the AARC.

Kallstrom, RRT, AE-C, FAARC, said that that there are several things that respiratory therapists should make sure their patients are aware of as the deadline for total phase-out of CFC inhalers hits on Jan. 1, 2009.

“Make sure patients are aware of this change. Many patients still don’t know about it or understand the differences between CFC and HFA powered inhalers,” said Kallstrom.

Important differences in the inhalers are outlined in a book written by the AARC last year, A Guide to Aerosol Delivery Devices. The distinction between the two types of medications begins on page 18.

Kallstrom offers these tips for respiratory therapists who are interacting with patients:

“As therapists, it’s our obligation to inform and educate with every patient interaction,” said Kallstrom. “If they have questions, we should be the source for their answers.”

Differences in Characteristics between CFC and HFA MDIs
Physical Component Delivery of Dose CFC HFA
   From a near-
   empty canister
Variable Consistent
   With variable
   ambient temperature
Variable Consistent (to -20° C)
Spray    
   Force Higher Impaction Lower (3 times)
   Temperature Colder Warmer (approx. 30° C)
   Volume Higher Lower
Taste Different from HFA Different from CFC
Breath-hold Less important with CFC More important with  HFA
Priming Important following short period of nonuse Longer time of nonuse allowed without priming

This page is located at: http://www.aarc.org/headlines/08/06/inhaler_phaseout/index.cfm


© American Association for Respiratory Care